An Investigational Scan (18F-Fluoro-1-Naphthol [18F-4FN] PET/CT) for Detecting Inflammation in Patients with Cancer

Inclusion Criteria

• Patient >= 18 years of age
• Patients with histologic diagnosis of solid or liquid tumor treated by immune checkpoint inhibitors (ICI) with evidence of or clinical suspicion of irAE
• Or patients with suspected inflammation of any cause
• Creatinine clearance (as estimated by Cockcroft Gault) >/= 30 mL/min/1.73 m^2
• Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subject
• Ability to provide written informed consent

Exclusion Criteria

• Pregnant or lactating women: pregnant women are excluded from this study because the effects of [18F]4FN in pregnancy are not known. Urine or serum pregnancy test (female =< 60 years of age or childbearing potential) within 24 hours of the PET scan
• Subjects with contraindications to the use of [18F]4FN including confirmed allergy
• Patients with a body weight of 400 pounds or more, or a body mass index (BMI) which precludes their entry into the bore of the PET/CT scanner, because the hardware is not intended to support that weight
• Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the physician may significantly interfere with study compliance
• Children below the age of 18 are excluded because of the unknown but potential risk of administration of radiopharmaceuticals to minors